Previous close | 82.85 |
Open | 81.97 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 81.90 - 82.18 |
52-week range | 73.79 - 93.98 |
Volume | |
Avg. volume | 603,130 |
Market cap | N/A |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 18 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
CVS warns it could cede Medicare Advantage market share as reimbursement rates pressure the company.
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem